Abstract
BackgroundTumor necrosis factor α (TNFα) blockers are known to reduce disease activity in patients with ankylosing spondylitis (AS). Data from a growing number of randomised controlled trials (RCTs) suggest them...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
